Ardena Invests €20 million for the Expansion of New Nanomedicine Facility in Netherlands
Introduction:
Ardena has invested €20 million in expanding its nanomedicine manufacturing facility in the Netherlands, achieving full Good Manufacturing Practice (GMP) certification.
Features:
The newly expanded facility spans 45,000 square feet and includes GMP-compliant Grade C and Grade D cleanrooms, specifically designed for nanomedicine production.
Additional enhancements include GMP production spaces, specialized laboratories for process development and analytical testing, as well as upgraded warehouse facilities.
This expansion enables the production and GMP release of a diverse range of nanomedicines, including advanced nanoparticulate drug delivery systems, imaging agents, and tissue engineering products.
The facility is equipped to handle various types of nanomedicines such as lipid-based nanoparticles (including LNPs, liposomes, and lipid micelles), polymeric nanoparticles (polymer micelles and dendrimer-based nanoparticles), and metal/metal oxide nanoparticles (including gold, silica, and iron oxide nanoparticles).
These upgrades will support Ardena in scaling its operations while ensuring rigorous quality standards and maintaining client satisfaction.
Additionally, Ardena's integrated services, such as aseptic fill-finish capabilities and bioanalysis expertise, offer comprehensive support for injectable nanomedicine formulations, providing a significant edge in clinical supply.
Specifications:
| Name : | Ardena |
| Type : | Expansion |
| Budget : | €20 Million |
